Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

PTC's fiscal first-quarter performance is likely to have been driven by demand for PLM and CAD in a tough selling environment and go-to-market realignment.

The stock's fall snapped a two-day winning streak.

Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $113 from $76 and keeps an Overweight rating on the shares. PTC ...

Loop Capital Markets analyst Yun Kim maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $240.00. The ...

This gene makes people sensitive to some bitter chemicals, such as phenylthiocarbamide (PTC) and propylthiouracil (PROP).

Have you ever wondered why some people cannot stand bitter foods like kale, broccoli, black coffee or dark chocolate, while ...

The U.S. Department of the Treasury and IRS on Jan. 10, 2025, released initial guidance regarding the production tax credit (PTC) for clean ...